PROTEOTECH, INC.

Basic Information

12040 115TH AVE N.E.
KIRKLAND, WA, 98034-

Company Profile

n/a

Additional Details

Field Value
DUNS: 28808843
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Tau Protein Aggregation Inhibitors for Tauopathies

    Amount: $2,271,931.00

    DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is characterized by brain amyloid plaques consisting of insoluble beta-amyloid protein (A?), and neurofibrillary tangles (NFTs) conta ...

    SBIR Phase II 2013 Department of Health and Human Services
  2. Identification of Novel Small Molecules as Tau Protein Aggregation Inhibitors for

    Amount: $770,675.00

    DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is characterized by brain amyloid plaques consisting of insoluble beta-amyloid (A2) and tau protein containing neurofibrillary ta ...

    SBIR Phase I 2011 Department of Health and Human Services
  3. Systemic AA Amyloidosis Inhibitors

    Amount: $1,330,463.00

    DESCRIPTION (provided by applicant): Systemic AA Amyloidosis is characterized by the accumulation of insoluble fibril deposits containing the AA amyloid protein in different organs throughout the body ...

    SBIR Phase II 2008 Department of Health and Human Services
  4. Laminin-Derived Protein Fragments as Inhibitors of Alzheimer's Amyloidosis

    Amount: $2,288,173.00

    DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is a degenerative brain disorder characterized clinically by progressive loss of memory, cognition, reasoning, and judgment that gradually ...

    SBIR Phase II 2006 Department of Health and Human Services
  5. Proteoglycans/Glycosaminoglycans in APP Transgenic Mice

    Amount: $520,841.00

    DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is a degenerative brain disorders characterized clinically by progressive loss of memory, cognition, reasoning, judgment and emotional sta ...

    SBIR Phase I 2004 Department of Health and Human Services
  6. Systemic AA Amyloidosis Inhibitors

    Amount: $264,984.00

    DESCRIPTION (provided by applicant): Systemic AA amyloidosis is characterized by the deposition and accumulation of insoluble fibrillar deposits containing the AA amyloid protein in a number of differ ...

    SBIR Phase I 2004 Department of Health and Human Services
  7. INHIBITORS OF ALZHEIMER'S DISEASE AMYLOIDOSIS

    Amount: $0.00

    DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is a degenerative brain disorder characterized clinically by progressive loss of memory, cognition, reasoning, judgment and emotional stab ...

    SBIR Phase I 2002 Department of Health and Human Services
  8. Amyloid Inhibiting Agent for Treatment of Alzheimer's

    Amount: $0.00

    Alzheimer's disease (AD) is a degenerative brain disorder characterized clinically by progressive loss of memory, cognition, reasoning, judgement and emotional stability that gradually leads to profou ...

    SBIR Phase I 2001 Department of Health and Human Services
  9. Amyloid Inhibiting Agent for Treatment of Alzheimer's

    Amount: $789,141.00

    Alzheimer's disease (AD) is a degenerative brain disorder characterized clinically by progressive loss of memory, cognition, reasoning, judgement and emotional stability that gradually leads to profou ...

    SBIR Phase II 2001 Department of Health and Human Services
  10. Alzheimer's Amyloid Plaque Persistence In Vivo

    Amount: $0.00

    DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is a degenerative brain disorder characterized clinically by progressive loss of memory, cognition, reasoning, judgment ...

    SBIR Phase I 2001 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government